Experienced in Choledocholithiasis

Amarender S. Puri

The, JK, IN 
Experienced in Choledocholithiasis
The, JK, IN 
OverviewLocationsClinical Research

Overview

Amarender Puri practices in The, India. Puri is rated as an Experienced expert by MediFind in the treatment of Choledocholithiasis. Their top areas of expertise are Celiac Disease, Malabsorption, Colitis, Viral Gastroenteritis, and Endoscopy.

Their clinical research consists of co-authoring 71 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 1 article in the study of Choledocholithiasis.

Locations

The, JK, India
Other Locations
Haryana, HR, India
CH Baktawar Singh Road, Medicity, Sector 38, Gurugram, 122 001, Sector, UP, India
New Delhi, DL, India
Dr DY Patil Medical College
Pune, MH, India
Gurgaon, HR, India
Delhi, DL, India
Ghaziabad, UP, India

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
Enrollment Status: Completed
Publish Date: October 14, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
Enrollment Status: Completed
Publish Date: May 31, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
View 1 Less Clinical Trial

71 Total Publications

The etiological profile of chronic organic non-bloody diarrhea in India: Emergence of inflammatory bowel disease as a dominant cause.
The etiological profile of chronic organic non-bloody diarrhea in India: Emergence of inflammatory bowel disease as a dominant cause.
Journal: Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology
Published: March 30, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Puri's expertise for a condition
ConditionClose
      View All 7 Advanced Conditions
      View All 33 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile